Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432404 · ClinicalTrials.gov registry record · Phase 4
Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity
A Phase 4 study of Bacterial Vaginosis, sponsored by University of Washington.
- Completed
- Registry status
- Phase 4
- Development phase
- 81
- Enrollment target
- 1
- Study location
NCT02432404: Completed Phase 4 study of Bacterial Vaginosis, sponsored by University of Washington.
NCT02432404 is a Phase 4 study of Bacterial Vaginosis that has completed, run by University of Washington. The registered enrollment target is 81 participants, below the 333-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02432404, a Phase 4 study of Bacterial Vaginosis, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who are HSV2-infected.
Primary Outcome
Change in Log10 quantity of bacteria detected (L. crisptatus, L. jensenii, L. iners, G. vaginalis, Megasphaera spp. BVAB2)
Conditions Studied
Interventions
- DRUG NuvaRing
Study Locations (1)
Washington
- UW Virology Research Clinic - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-03 |
| Est. Completion | 2021-11 |
| Phase | Phase 4 |
What the finished NCT02432404 record still lists
NCT02432404 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 333-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Bacterial Vaginosis appearing as the primary indexed condition, and to 1 intervention - of which NuvaRing is the first listed.
NCT02432404 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02432404 about?
NCT02432404 is a clinical study titled "Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity". To assess potential benefits associated with both intermittent (use for 3 weeks, remove for 1 week, as defined in the package insert) and continuous (use for 4 weeks, then replace) CVR use among women either with BV or at high risk for BV. The investigators will also recruit women who are HSV2-infec...
What is the current status of trial NCT02432404?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 81 participants. The study started on 2016-03. Estimated completion is 2021-11.
What conditions does trial NCT02432404 study?
This clinical trial studies the following conditions: Bacterial Vaginosis.
What interventions are being tested in trial NCT02432404?
The interventions under investigation include: NuvaRing (DRUG).
Who is sponsoring clinical trial NCT02432404?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02432404 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Vaginosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02432404's enrollment target sits among peer trials
81 11th of 15 higher than 4 of 15 other Bacterial Vaginosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Vaginosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Bacterial Vaginosis (BV) With Tinidazole
COMPLETED · Phase 4
-
Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
COMPLETED · Phase 4
-
Clinical Protocol CERN Feasibility Study
RECRUITING · NA
-
Prospective Data Bank Creation to Study Vaginal Conditions
RECRUITING
-
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
RECRUITING · Early Phase 1
-
Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia